2020
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaLA PDACUnresectable pancreatic ductal adenocarcinomaInduction FOLFIRINOXConsolidative radiotherapyOverall survivalAdvanced unresectable pancreatic ductal adenocarcinomaSingle-center retrospective reviewMeaningful survival benefitMedian overall survivalUnresectable pancreatic cancerR0 resection rateKaplan-Meier methodSingle institution experienceBenefits of surgeryLog-rank testConsolidative radiationDefinitive radiationLA patientsPreoperative radiationResection rateSurgery patientsSurvival benefitSurvival impactImproved survival
2018
Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal Of Gastrointestinal Oncology 2018, 9: 982-988. PMID: 30603116, PMCID: PMC6286925, DOI: 10.21037/jgo.2018.04.03.Peer-Reviewed Original ResearchDistant metastasis-free survivalAdvanced pancreatic cancerConsolidative chemoradiationOverall survivalLocal controlPancreatic cancerMedian distant metastasis-free survivalCox proportional hazards modelCommon Terminology CriteriaEfficacy of FOLFIRINOXMedian overall survivalMore T4 tumorsMulti-agent chemotherapyR0 surgical resectionUse of FOLFIRINOXMonths of chemotherapyResponse Evaluation CriteriaKaplan-Meier analysisMetastasis-free survivalProportional hazards modelTerminology CriteriaProspective trialRadiographic responseSurgical resectionT3 tumors